A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha‐2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)—AGMT_CML 1Sonja Heibl, Josef Thaler, Thomas Lion et al.|Hematological Oncology|2020Cited by 11
Author response for "A Phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha 2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia not achieving a deep molecular response (MR 4.5) – AGMT_CML 1"Sonja Heibl, Josef Thaler, Veronika Buxhofer‐Ausch et al.|Unknown|2020Cited by 0